Supported by

Tricuspid / Pulmonary valve

Latest tricuspid content in interventional cardiology - research, practice, and education

Endovascular treatments for complications of the tricuspid or pulmonary valve, such as the treatment for tricuspid regurgitation (TR), are at an early stage of clinical development with many novel devices being introduced each year. This topic explores the different parameters of this emerging field with information on the latest research, emerging tools, devices and techniques, vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography as well as understanding bleeding risks or patient selection. Find out more…

Filtered By
Tricuspid / Pulmonary valve

523 results

Procedural imaging for tricuspid valve interventions

15 Feb 2026 – From PCR Tokyo Valves 2026

Dedicated to procedural imaging for tricuspid valve interventions, this session elucidates anatomical and pathophysiological features critical for successful transcatheter procedures. It emphasizes technical aspects of TEE and ICE imaging, including 3D multiplanar reconstruction, and offers case-based learning to refine imaging skills and optimize procedural outcomes.

Procedural imaging for tricuspid valve interventions

Guidelines update

15 Feb 2026 – From PCR Tokyo Valves 2026

This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...

Guidelines update

Future devices and techniques for structural heart disease

15 Feb 2026 – From PCR Tokyo Valves 2026

This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.

Future devices and techniques for structural heart disease

Late-breaking trials of PCR Tokyo Valves 2026

14 Feb 2026 – From PCR Tokyo Valves 2026

This session presents pivotal late-breaking trials from PCR Tokyo Valves 2026, offering one-year outcomes and real-world experiences in transcatheter valve therapies. Highlights include the AltaValve early feasibility study on atrial fixation TMVR, invasive registry insights on prosthesis-patient mismatch post-TAVR, and registry data on tricuspid and mitral...

Late-breaking trials of PCR Tokyo Valves 2026

TEER in complex tricuspid regurgitation - LIVE case

14 Feb 2026 – From PCR Tokyo Valves 2026

A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.

Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.

LIVE Educational Case...

TEER in complex tricuspid regurgitation - LIVE case

Hot topics and evidence on structural interventions in 2025 and 2026

14 Feb 2026 – From PCR Tokyo Valves 2026

Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...

Hot topics and evidence on structural interventions in 2025 and 2026

Getting ready for tricuspid TEER: key steps in building a successful programme

14 Feb 2026 – From PCR Tokyo Valves 2026

Prepare to establish a successful tricuspid TEER programme by understanding essential components such as systematic echocardiographic and clinical assessments for patient selection, procedural fundamentals, and programme development supported by clinical evidence.

Getting ready for tricuspid TEER: key steps in building a successful programme

Patient selection for tricuspid TEER in 2026

14 Feb 2026 – From PCR Tokyo Valves 2026

This session focuses on optimizing patient selection for tricuspid transcatheter edge-to-edge repair (TEER) in 2026. It integrates anatomical, haemodynamic, and clinical criteria to identify ideal candidates, explores evolving treatment boundaries between TEER, transcatheter tricuspid valve replacement (TTVR), and medical management, and applies evidence from key trials...

Patient selection for tricuspid TEER in 2026

Team approach to structural heart disease: how to handle unexpected situations

14 Feb 2026 – From PCR Tokyo Valves 2026

This session highlights the multidisciplinary team approach to managing structural heart disease, focusing on responses to unexpected intraoperative and postoperative situations. It features real-world experiences from a TAVI radiologic technologist, clinical engineer, TEER sonographer, and TEER nurse, emphasizing their respective roles in addressing intraoperative events, sudden...

Team approach to structural heart disease: how to handle unexpected situations

Mastering techniques from basic to complex - Tricuspid TEER fundamentals

13 Feb 2026 – From PCR Tokyo Valves 2026

Gain foundational knowledge in tricuspid TEER by understanding anatomical criteria for patient suitability, key procedural steps, and device techniques, enhanced by simulation-based procedural training.

Mastering techniques from basic to complex - Tricuspid TEER fundamentals